About Tosymra®

Tosymra® is an acute migraine treatment that offers:

  • Fine, mist-like spray.
  • Discreet size.
  • Single use device, no priming required.

Did you know?

Different migraines require different therapy approaches. Migraine is a debilitating disease that can be further complicated when certain symptoms are present.

73%

of patients with migraine have experienced nausea (with or without vomiting) during migraine attacks.4

How can Tosymra® help?

Tosymra® is a prescription medicine used for the acute treatment of migraine with or without aura in adults.

If you suffer from any of the following, Tosymra® may be able to help:

Migraine with nausea

This can make it difficult to take oral medication4

Morning migraine

Nearly half of all migraine attacks occur between 4 and 9 a.m.5

Rapid-onset migraine

A migraine that reaches
full force quickly

Do not use Tosymra® if you have heart problems, narrowing of blood vessels or uncontrolled high blood pressure. These are not all of the reasons you should not use Tosymra®. See the Important Safety Information, and speak with your healthcare provider for more information about whether Tosymra® is right for you.

How it works

Tosymra® is formulated with Intravail® technology to help the medication be absorbed into the bloodstream so it can work quickly. It works as fast as an injection, providing migraine pain relief in as little as 10 minutes for some patients with just one spray (13% vs. 5% for placebo).*1-3

Efficacy of Tosymra® is based on relative bioavailability to subcutaneous sumatriptan at a dose of 4 mg. In a clinical study, this dose of sumatriptan resulted in 57% of patients achieving pain relief at 2 hours vs. 21% for placebo.

*Time to onset and degree of pain relief varies by patient.

References

  1. Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2021.
  2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
  3. Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.
  4. Newman LC. Why triptan treatment can fail: focus on gastrointestinal manifestations of migraine. Headache. 2013;53 Suppl 1:11-16.
  5. Top 10 migraine triggers and how to deal with them. American Migraine Foundation. https://americanmigrainefoundation.org/resource-library/top-10-migraine-triggers-and-how-to-deal-with-them/. Published July 27, 2017. Accessed October 2020